Jpmorgan Chase & CO Sensei Biotherapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Sensei Biotherapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 702 shares of SNSE stock, worth $6,339. This represents 0.0% of its overall portfolio holdings.
Number of Shares
702
Previous 705
0.43%
Holding current value
$6,339
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding SNSE
# of Institutions
23Shares Held
1.97MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA586KShares$5.29 Million0.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX450KShares$4.06 Million0.02% of portfolio
-
Catalio Capital Management, LP New York, NY294KShares$2.66 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny177KShares$1.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA151KShares$1.36 Million0.0% of portfolio
About Sensei Biotherapeutics, Inc.
- Ticker SNSE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,720,300
- Market Cap $277M
- Description
- Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune res...